Empagliflozin Ameliorates Adverse Left Ventricular Remodeling in Nondiabetic Heart Failure by Enhancing Myocardial Energetics.

Carlos G Santos-Gallego,Juan Antonio Requena-Ibanez,Rodolfo San Antonio,Kiyotake Ishikawa,Shin Watanabe,Belen Picatoste,Eduardo Flores,Alvaro Garcia-Ropero,Javier Sanz,Roger J Hajjar,Valentin Fuster,Juan J Badimon

Journal of the American College of Cardiology（2019）

引用 419|浏览18

暂无评分

摘要

Empagliflozin ameliorates adverse cardiac remodeling and heart failure in a nondiabetic porcine model. Empagliflozin switches myocardial fuel utilization away from glucose toward KB, FFA, and BCAA, thereby improving myocardial energetics, enhancing LV systolic function, and ameliorating adverse LV remodeling.

查看译文

关键词

animal models,cardiac remodeling,diabetes,heart failure,myocardial metabolism,SGLT2 inhibition

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要